RNTX - NASDAQ

RT

Rein Therapeutics Inc.

RNTXยทNASDAQ

$1.87

+0.53%
HealthcareMedical - Pharmaceuticals

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$52.43M
EPS-1.9600
P/E Ratio-0.96
Earnings Date05/21/2026
RT

Rein Therapeutics Inc. Fair Value Envelope

RNTX ยท NASDAQ

Our analysis suggests that RNTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.87, this represents a potential HIDDEN relative to our calculated worth for Rein Therapeutics Inc..

HIDDEN
Intrinsic Value
Current Price: $1.87

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$252.3M
+ Cash & Equivalents$3.2M
Firm Value-$249.1M
- Debt$0
Equity Value-$249.1M
/ Shares Outstanding28,039,000B
DCF Value-$9
OVERVALUED BY 575%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$21.9M
-$24.8M
-$28.0M
-$31.7M
-$35.9M
-$40.6M
-$46.0M
-$52.0M
-$58.8M
-$66.6M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$21.9M
-$24.8M
-$28.0M
-$31.7M
-$35.9M
-$40.6M
-$46.0M
-$52.0M
-$58.8M
-$66.6M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$20.3M
-$21.2M
-$22.3M
-$23.3M
-$24.4M
-$25.6M
-$26.8M
-$28.1M
-$29.4M
-$30.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your RNTX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.